{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:57:07Z","timestamp":1786636627232,"version":"build-2736575974"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2012]]},"DOI":"10.4103\/0253-7613.91858","type":"journal-article","created":{"date-parts":[[2012,1,14]],"date-time":"2012-01-14T15:50:41Z","timestamp":1326556241000},"page":"4","source":"Crossref","is-referenced-by-count":12,"title":["Pulmonary arterial hypertension: Advances in pathophysiology and management"],"prefix":"10.4103","volume":"44","author":[{"given":"DineshK","family":"Badyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PChris","family":"Baby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davis","family":"Cherian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0253-7613.91858-1","first-page":"35S","volume-title":"Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines","author":"Badesch","year":"2004","journal-title":"Chest"},{"key":"key-10.4103\/0253-7613.91858-2","first-page":"1917","volume-title":"Medical therapy for pulmonary arterial hypertension.Updated ACCP evidence-based clinical practice guidelines","author":"Badesch","year":"2007","journal-title":"Chest"},{"key":"key-10.4103\/0253-7613.91858-3","first-page":"2438","volume-title":"Cardiovascular disease in non-western countries","author":"Reddy","year":"2004","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0253-7613.91858-4","first-page":"984","volume-title":"Pediatric heart care in India","author":"Kumar","year":"2008","journal-title":"Heart"},{"key":"key-10.4103\/0253-7613.91858-5","first-page":"507","volume-title":"Epidemiological study of congenital heart disease","author":"Chadha","year":"2001","journal-title":"Indian J Pediatr"},{"key":"key-10.4103\/0253-7613.91858-6","first-page":"57","volume-title":"Epidemiology of congenital and rheumatic heart disease in children","author":"Gupta","year":"1992","journal-title":"J Indian Med Assoc"},{"key":"key-10.4103\/0253-7613.91858-7","unstructured":"Kumar RK, Rammohan R, Narula J, Kaplan EL. Epidemiology of streptococcal pharyngitis, rheumatic fever and rheumatic heart disease. In: Narula J, Virmani R, Reddy KS, Tandon R, editors. Rheumatic fever, Washington, DC; American Registry of Pathology; 1999. p. 41-78."},{"key":"key-10.4103\/0253-7613.91858-8","first-page":"14S","volume-title":"Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines","author":"McGoon","year":"2004","journal-title":"Chest"},{"key":"key-10.4103\/0253-7613.91858-9","first-page":"249","volume-title":"Increased plasma serotonin in primary pulmonary hypertension","author":"Herve","year":"1995","journal-title":"Am J Med"},{"key":"key-10.4103\/0253-7613.91858-10","first-page":"70","volume-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","author":"Christman","year":"1992","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0253-7613.91858-11","first-page":"583","volume-title":"Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension","author":"White","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"key-10.4103\/0253-7613.91858-12","first-page":"1178","volume-title":"Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells","author":"Sakao","year":"2005","journal-title":"Faseb J"},{"key":"key-10.4103\/0253-7613.91858-13","first-page":"44","volume-title":"Calcium and TRP channels in pulmonary vascular smooth muscle cell proliferation","author":"Landsberg","year":"2004","journal-title":"News Physiol Sci"},{"key":"key-10.4103\/0253-7613.91858-14","first-page":"790","volume-title":"Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins","author":"Morrell","year":"2001","journal-title":"Circulation"},{"key":"key-10.4103\/0253-7613.91858-15","first-page":"L872","volume-title":"Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate pulmonary arterial hypertension","author":"McMurtry","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"key-10.4103\/0253-7613.91858-16","first-page":"1479","volume-title":"Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension","author":"McMurtry","year":"2005","journal-title":"J Clin Invest"},{"key":"key-10.4103\/0253-7613.91858-17","first-page":"194","volume-title":"Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension?","author":"Eddahibi","year":"2002","journal-title":"J Lab Clin Med"},{"key":"key-10.4103\/0253-7613.91858-18","first-page":"1646","volume-title":"Signal transduction by the TGF-beta superfamily","author":"Attisano","year":"2002","journal-title":"Science"},{"key":"key-10.4103\/0253-7613.91858-19","first-page":"278","volume-title":"Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension","author":"Moreno-Vinasco","year":"2008","journal-title":"Physiol Genomics"},{"key":"key-10.4103\/0253-7613.91858-20","first-page":"737","volume-title":"Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene","author":"Deng","year":"2000","journal-title":"Am J Hum Genet"},{"key":"key-10.4103\/0253-7613.91858-21","first-page":"741","volume-title":"Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family","author":"Thomson","year":"2000","journal-title":"J Med Genet"},{"key":"key-10.4103\/0253-7613.91858-22","first-page":"1486","volume-title":"Emerging concepts and translational priorities in pulmonary arterial hypertension","author":"Michelakis","year":"2008","journal-title":"Circulation"},{"key":"key-10.4103\/0253-7613.91858-23","first-page":"1533","volume-title":"Primary pulmonary hypertension","author":"Runo","year":"2003","journal-title":"Lancet"},{"key":"key-10.4103\/0253-7613.91858-24","first-page":"159","volume-title":"Endothelial dysfunction in pulmonary hypertension","author":"Budhiraja","year":"2004","journal-title":"Circulation"},{"key":"key-10.4103\/0253-7613.91858-25","first-page":"609","volume-title":"Appetite suppressant drugs and the risk of primary pulmonary hypertension","author":"Abenhaim","year":"1996","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0253-7613.91858-26","first-page":"5S","volume-title":"Clinical classification of pulmonary hypertension","author":"Simmoneau","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/0253-7613.91858-27","first-page":"40S","volume-title":"Diagnosis and differential assessment of pulmonary arterial hypertension","author":"Barst","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/0253-7613.91858-28","first-page":"S43","volume-title":"Updated clinical classification of pulmonary hypertension","author":"Simonneau","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/0253-7613.91858-29","first-page":"1052","volume-title":"Electrocardiography in the diagnosis of right ventricular hypertrophy in children","author":"Puchalski","year":"2006","journal-title":"Pediatrics"},{"key":"key-10.4103\/0253-7613.91858-30","first-page":"1214","volume-title":"Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension","author":"Raymond","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/0253-7613.91858-31","first-page":"1313","volume-title":"Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension","author":"Fijalkowska","year":"2006","journal-title":"Chest"},{"key":"key-10.4103\/0253-7613.91858-32","first-page":"487","volume-title":"Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension","author":"Nagaya","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.4103\/0253-7613.91858-33","first-page":"844","volume-title":"Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension","author":"Torbicki","year":"2003","journal-title":"Circulation"},{"key":"key-10.4103\/0253-7613.91858-34","first-page":"731","volume-title":"Prevalence and correlates of septal delayed contrast enhancement in patients with pulmonary hypertension","author":"Sanz","year":"2007","journal-title":"Am J Cardiol"},{"key":"key-10.4103\/0253-7613.91858-35","first-page":"387","volume-title":"The 6-minute walk test: A quick measure of functional status in elderly adults","author":"Enright","year":"2003","journal-title":"Chest"},{"key":"key-10.4103\/0253-7613.91858-36","first-page":"139","volume-title":"New predictors of outcome in idiopathic pulmonary arterial hypertension","author":"Kawut","year":"2008","journal-title":"Chest"},{"key":"key-10.4103\/0253-7613.91858-37","first-page":"76","volume-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0253-7613.91858-38","first-page":"70","volume-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","author":"Christman","year":"1992","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0253-7613.91858-39","first-page":"56S","volume-title":"Prostanoid therapy for pulmonary arterial hypertension","author":"Badesch","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/0253-7613.91858-40","first-page":"2119","volume-title":"Beraprost therapy for pulmonary arterial hypertension","author":"Barst","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/0253-7613.91858-41","first-page":"296","volume-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0253-7613.91858-42","first-page":"800","volume-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analog, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.4103\/0253-7613.91858-43","first-page":"683","volume-title":"Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: A prospective, multicentre, open label, 12-week trial","author":"Tapson","year":"2006","journal-title":"Chest"},{"key":"key-10.4103\/0253-7613.91858-44","first-page":"322","volume-title":"Inhaled iloprost for severe pulmonary hypertension","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0253-7613.91858-45","first-page":"1895","volume-title":"Clinical efficacy and survival with first line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension","author":"Opitz","year":"2005","journal-title":"Eur Heart J"},{"key":"key-10.4103\/0253-7613.91858-46","first-page":"H445","volume-title":"Impaired endothelium dependent relaxations in hypertensive resistance arteries involve cyclooxygenase pathway","author":"Diedrich","year":"1990","journal-title":"Am J Physiol"},{"key":"key-10.4103\/0253-7613.91858-47","first-page":"244","volume-title":"Survival with first line Bosentan in patients with primary pulmonary hypertension","author":"Mclaughlin","year":"2005","journal-title":"Eur Respir J"},{"key":"key-10.4103\/0253-7613.91858-48","first-page":"1025","volume-title":"Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol","author":"Sitbon","year":"2005","journal-title":"Thorax"},{"key":"key-10.4103\/0253-7613.91858-49","first-page":"372","volume-title":"Pharmokinetics, safety and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension","author":"Barst","year":"2003","journal-title":"Clin Pharmocol Ther"},{"key":"key-10.4103\/0253-7613.91858-50","first-page":"171","volume-title":"Endothelin receptor antagonists for pulmonary arterial hypertension.Rationale and place in therapy","author":"Price","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"key-10.4103\/0253-7613.91858-51","first-page":"119","volume-title":"Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension","author":"Safdar","year":"2011","journal-title":"Vasc Health Risk Manag"},{"key":"key-10.4103\/0253-7613.91858-52","first-page":"2148","volume-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","author":"Galie","year":"2005","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0253-7613.91858-53","first-page":"1488","volume-title":"Differences in Hemodynamic and Oxygenation Responses to Three Different Phosphodiesterase-5 Inhibitors in Patients With Pulmonary Arterial Hypertension","author":"Ghofrani","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/0253-7613.91858-54","first-page":"139","volume-title":"Treprostinil based therapy in the treatment of moderate to severe pulmonary arterial hypertension","author":"Benza","year":"2008","journal-title":"Chest"},{"key":"key-10.4103\/0253-7613.91858-55","first-page":"164","volume-title":"Graded balloon atrial septostomy in sever pulmonary hypertension","author":"Kothari","year":"2002","journal-title":"Indian Heart J"},{"key":"key-10.4103\/0253-7613.91858-56","first-page":"950","volume-title":"The Registry of the International Society for Heart and Lung Transplantation: 19 th official report - 2002","author":"Hertz","year":"2002","journal-title":"J Heart Lung Transplant"},{"key":"key-10.4103\/0253-7613.91858-57","first-page":"2011","volume-title":"Chronic thromboembolic pulmonary hypertension","author":"Hoeper","year":"2006","journal-title":"Circulation"},{"key":"key-10.4103\/0253-7613.91858-58","first-page":"444","volume-title":"Biventricular support with a Jarvik 200- ventricular assist device in a calf model of pulmonary hypertension","author":"Kindo","year":"2004","journal-title":"ASAIO J"},{"key":"key-10.4103\/0253-7613.91858-59","first-page":"939","volume-title":"Angiotensin converting enzyme inhibition delays pulmonary vascular neointimal formation","author":"Okada","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.4103\/0253-7613.91858-60","first-page":"1020","volume-title":"Update on Pulmonary Hypertension 2009","author":"Gladwin","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.4103\/0253-7613.91858-61","first-page":"780","volume-title":"Long term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","author":"Sitbon","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/0253-7613.91858-62","first-page":"865","volume-title":"Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension","author":"Nagaya","year":"2000","journal-title":"Circulation"},{"key":"key-10.4103\/0253-7613.91858-63","first-page":"1214","volume-title":"Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension","author":"Raymond","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/0253-7613.91858-64","first-page":"1339","volume-title":"Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension","author":"Petkov","year":"2003","journal-title":"J Clin Invest"},{"key":"key-10.4103\/0253-7613.91858-65","first-page":"133","volume-title":"Gene therapy for pulmonary hypertension: prospects and challenges.Expert Opin","author":"Reynolds","year":"2011","journal-title":"Biol Ther"},{"key":"key-10.4103\/0253-7613.91858-66","first-page":"1412","volume-title":"Imatinib for the treatment of pulmonary arterial hypertension","author":"Ghofrani","year":"2005","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0253-7613.91858-67","first-page":"152","volume-title":"Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension","author":"Patterson","year":"2006","journal-title":"Ann Intern Med"},{"key":"key-10.4103\/0253-7613.91858-68","first-page":"1151","volume-title":"Rho A and Rho kinase activation in human pulmonary hypertension: Role of 5-HT signalling","author":"Guilluy","year":"2009","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:59:10Z","timestamp":1786633150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0253-7613.91858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"alternative-id":["91858"],"URL":"https:\/\/doi.org\/10.4103\/0253-7613.91858","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2012]]}}}